THE TEAM
Co-Founders
Lana Volokh, PhD
Co-founder & CEO, Director
Scientist and executive (GE Healthcare Israel and USA, John Hopkins University)
Dr. Volokh has over 20 years of experience in healthcare, covering R&D, system engineering, tech management, clinical research, IP management, product development, market access, and regulatory strategy. Her diverse background includes roles at GE Healthcare (Israel/USA), Johns Hopkins University, and startups like Arineta, Applied Spectral Imaging, and Theranica. Instrumental in establishing and managing industry-academia collaborations, Dr. Volokh is a co-inventor on multiple patents, a co-author of research publications, and has authored a book chapter. As an accomplished executive, she has played a crucial role in developing products that integrate advanced technology with clinical applications.
Alex Tendler, PhD
Co-founder & CTO, Director
Scientist, engineer and entrepreneur Intel, Techion, Haifa University, Rainbow Medical
Dr. Tendler is a seasoned entrepreneur and researcher with extensive experience in life sciences and biomedical engineering, including drug delivery, neuroscience, and medical devices. He has a deep understanding of various research methodologies and techniques and excels in designing and overseeing lab and clinical trials, IP development, and scientific writing. Dr. Tendler has led innovative R&D teams at Intel and Rainbow Medical (Brain Balance, DiscCure), is a co-inventor on multiple patents, and has received awards from entities like the National Network of Excellence in Neuroscience. His leadership has been key in driving multidisciplinary projects from concept to implementation and clinical research.
Chief Scientist
CFO
Yevgeny Tendler MD, PhD
Scientist, expert in cell biology
(Clinical Biochemistry, Rambam
Medical Center)
With three decades of research on the p53 protein, Dr. Tendler has gained extensive expertise in this field. His contributions include the characterization of p53 across multiple species.
This groundbreaking revelation forms the cornerstone of AnserBio's therapeutic approach, translating Dr. Tendler's pioneering work to advance cancer treatment strategies.
Roman Katz
CFO
Roman Katz is a Senior Manager at YBO C.P.A. firm, where he has served for the past eight years as a part-time CFO or Financial Controller for several Israeli subsidiaries of global high-tech companies, including Medtronic, Bio-Rad, IFS, and Toluna. Roman has also held key financial roles as CFO or Finance Manager at Sealantis—where he led the company’s successful exit in 2019—and at Protean Tecs, guiding it from its inception to a stable revenue phase. A certified C.P.A. with nearly 20 years of experience, Roman began his career at PwC. He holds a degree from Haifa University and an MBA from Ruppin College.
Team
Bracha Shraibman, PhD
Production and process development
team lead
Bracha has over 12 years of academic and industrial experience in innovative drug development, specializing in cell biology, nano-sized vesicles, biochemistry, complex proteins and genome engineering. Previously a Principal Scientist at Lonza, she holds a PhD in Biology from Technion - Israel Institute of Technology, focusing on biochemistry and personalized immunotherapy.
Gil Shalev, PhD
R&D Scientist
Expert in protein purification
Experience in academic-pharma collaborations and early drug development
Dr. Shalev is an expert in protein purification, drug development, and cancer research. He has extensive experience in academia-pharma collaborations and early-stage drug development, working with Prof. Aaron Ciechanover and at Technion, Protalix, Danyel Biotech, and Quark Pharmaceuticals. He is also a co-author of patents and publications.
Ksenia Magidey Klein, PhD
R&D Scientist
Ksenia has accumulated experience in cell biology, stem cells, preclinical and translational cancer research, early therapeutics development, and pharma R&D partnerships. She has previously been with Minovia Therapeutics, Rappaport Faculty of Medicine of the Technion, Aminolab Ltd. Ksenia has co-authored multiple publications.
Albina Lin, MSc
R&D
Biologic drug development, analytical assays and process development
Ms. Lin brings a decade of expertise in biologic drug development, analytical assays, and process development from various roles at Protein Production Services, Protein Laboratories Rehovot, Mike Fainzilber Lab at the Weizmann Institute of Sciences, and Hy Laboratories. Her skills and expertise encompass a wide range of advanced laboratory techniques and processes.
Alla Savchuk, BSc
Process technician
Ms. Savchuk is a skilled process technician with deep knowledge of AnserBio production techniques and the maintenance of cell lines, including both stable lines and primary cultures.
Scientific Advisors
Daniel Offen, PhD
Exosome based therapeutics
Internationally recognized researcher, inventor, innovator and co-founder of several biotechnology companies, Head
of Translational Neuroscience Laboratory at TAU
Prof. Offen's research has focused on gene editing and various methods to deliver therapeutics into the brain, such as stem cells and nanoparticles. His work has been featured in over 200 publications and cited more than 15,000 times. Prof. Offen has co-invented dozens of patents that have laid the foundation for biotech companies and startups like Brainstorm Cell Therapeutics (NASDAQ: BCLI)
and eggXYt.
Avi Treves, PhD
Immuno-oncology and cell therapy
Expert in translational and clinical R&D and product development, immuno-oncology and cell therapy.
Co-founder of several biotech companies, including NASDAQ-traded Gamida Cell
Dr. Treves is an expert in business development, funding, and translational research, with a focus on biotech regulatory and clinical development. He specializes in regenerative medicine, stem cell technologies, and immuno-oncology. With a PhD from the Weizmann Institute and a postdoctoral fellowship from Stanford University, he has co-authored 100+ publications, holds 10 patents, and advises various biotech companies.
Prof. Galit Lahav, PhD
Novartis Professor and Chair, Department of Systems Biology, Harvard Medical School
Prof. Galit Lahav is an internationally recognized, award winning researcher and serves as Chair of the Department of Systems Biology at Harvard Medical School. She pioneered computational and quantitative experimental approaches to study cancer at the single-cell level. Her lab pioneered live single-cell imaging to quantify the tumor suppressor protein p53 and has established p53 dynamics as an important control mechanism, yielding critical insights into the tumor-suppressing mechanisms. Prof. Lahav earned her PhD from the Technion, Israel Institute of Technology and completed a postdoctoral fellowship at the Weizmann Institute. She now leads initiatives advancing single-cell technologies, data analysis through systems thinking and predictive models of biology, to unlock new insights into health and disease.
Board Members
David Sidransky, MD
Board Member/Director
Renowned oncologist, research scientist, professor of Oncology and Cellular & Molecular Medicine at JHU, founder of several biotechnology companies
Dr. Sidransky is a renowned oncologist and Professor of Oncology at Johns Hopkins University. He was among the first to identify p53 mutations in human cancers and has published over 600 papers in cancer biology, diagnostics, and therapeutics. As a co-founder and Managing Partner of Israel Biotech Fund, he also founded Oncormed Pharmaceuticals and Champions Oncology. He serves on multiple scientific advisory boards.
Yekaterina Chudnovsky
Board Member/Director
Yekaterina 'Katie' Chudnovsky is an attorney, venture investor, and patient advocate dedicated to advancing cancer research. She funds rare cancer projects, chairs the GI Research Foundation at the University of Chicago, and serves on the boards of Elicio Therapeutics, Immix Biopharma, XCures, and the Colorectal Cancer Alliance, as well as being a Board Observer for MiNK Therapeutics. Katie holds a BA from Northwestern University and a JD from DePaul University.
Consultants & Collaborators
Xavier Grana, PhD
Temple University
Immortalization
Dr. Graña is a Molecular Cell Biologist and Biochemist with expertise in the field of cell cycle regulation and control of gene expression. His research focuses on cell cycle control mechanisms in mammalian cells and their deregulation in cancer, including role of cyclins, cyclin dependent kinases (CDKs), Ser/Thr protein phosphatases and tumor suppressor genes. Dr. Grana is a renowned expert in innovative cell immortalization strategies, including CRISPER.
Tomer Cooks, PhD
Ben-Gurion University
Assistant Professor of Immunology
and Microbiology
During his doctoral studies, Dr. Cooks helped develop a unique ionized alpha radiation treatment for solid tumors, now in advanced trials worldwide. His research expanded to the tumor microenvironment and exosomes. The CooksLab specializes in cell communication via extracellular vesicles and the TP53 gene, striving to apply innovative approaches for cancer patient benefit.